|Mr. Paul F. Truex||Exec. Chairman||N/A||N/A||1969|
|Mr. John Craig Thompson||CEO & Director||715.3k||N/A||1967|
|Ms. May Liu||Sr. VP of Fin. & Admin. and Principal Accounting Officer||N/A||N/A||1976|
|Dr. Paul Adams Ph.D.||Sr. VP of Global Regulatory Affairs and Compliance||N/A||N/A||1963|
|Drew McManigle||Chief Liquidating Officer & Director||N/A||N/A||N/A|
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Anthera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.